Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Hematopoietic SCT for the treatment of multiple sclerosis

Bone Marrow Transplantation volume 45, pages 1671–1681 (2010)Cite this article

Subjects

Abstract

Multiple sclerosis (MS) is the leading autoimmune indication for autologous hematopoietic SCT (aHSCT). Patient selection criteria and transplant interventions have been refined through a series of cohort and registry studies. High- and low-intensity chemotherapy-based conditioning regimens have been used, creating trade-offs between toxicity and effectiveness. TBI has been associated with greater toxicity and poor outcomes. aHSCT stops MS relapses and lessens the disability in malignant MS, which otherwise rapidly incapacitates patients. Better responses occur in progressive MS earlier in the disease when it has a more inflammatory nature. aHSCT prevents further disability in many patients, but some actually recover from their infirmities. Current regimens and supportive care result in very low morbidity and mortality. MS patients experience unique complications in addition to the expected toxicities. Cytokines used alone for stem-cell mobilization may induce MS flares but are safe to be used in combination with steroids or cytotoxic agents. Urinary tract infections, herpes virus reactivation and an engraftment syndrome may occur early after aHSCT. Rarely secondary autoimmune diseases have been reported late after HSCT. Increasing experience in caring for patients with MS has reduced the frequency and severity of toxicity. Conceived as an opportunity to ‘reboot’ a tolerant immune system, aHSCT is successful in treating patients with MS that is refractory to conventional immunomodulatory drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Giovannoni G, Ebers G . Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007; 20: 261–268.

    Article  PubMed  Google Scholar 

  2. Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

    Article  CAS  PubMed  Google Scholar 

  3. Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC . Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 2009; 5: 672–682.

    Article  PubMed  Google Scholar 

  4. Filippi M, Horsfield MA, Morrissey SP, MacManus DG, Rudge P, McDonald WI et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44: 635–641.

    Article  CAS  PubMed  Google Scholar 

  5. van Bekkum DW . Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201–222.

    Article  CAS  PubMed  Google Scholar 

  6. Burt RK, Padilla J, Begolka WS, Canto MC, Miller SD . Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998; 91: 2609–2616.

    CAS  PubMed  Google Scholar 

  7. Cassiani-Ingoni R, Muraro PA, Magnus T, Reichert-Scrivner S, Schmidt J, Huh J et al. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol 2007; 66: 637–649.

    Article  PubMed  Google Scholar 

  8. Van Laar JM, Tyndall A . Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 2003; 10: 57–65.

    Article  PubMed  Google Scholar 

  9. Passweg J, Gratwohl A, Tyndall A . Hematopoietic stem cell transplantation for autoimmune disorders. Curr Opin Hematol 1999; 6: 400–405.

    Article  CAS  PubMed  Google Scholar 

  10. McAllister LD, Beatty PG, Rose J . Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997; 19: 395–397.

    Article  CAS  PubMed  Google Scholar 

  11. McKendry RJ, Huebsch L, Leclair B . Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. Arthritis Rheum 1996; 39: 1246–1253.

    Article  CAS  PubMed  Google Scholar 

  12. Lopez-Cubero SO, Sullivan KM, McDonald GB . Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998; 114: 433–440.

    Article  CAS  PubMed  Google Scholar 

  13. Mancardi GL, Murialdo A, Rossi P, Gualandi F, Martino G, Marmont A et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005; 11: 367–371.

    Article  PubMed  Google Scholar 

  14. Fagius J, Lundgren J, Oberg G . Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009; 15: 229–237.

    Article  CAS  PubMed  Google Scholar 

  15. Kimiskidis V, Sakellari I, Tsimourtou V, Kapina V, Papagiannopoulos S, Kazis D et al. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Mult Scler 2008; 14: 278–283.

    Article  CAS  PubMed  Google Scholar 

  16. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 244–253.

    Article  CAS  PubMed  Google Scholar 

  17. Carreras E, Saiz A, Marín P, Martínez C, Rovira M, Villamor N et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003; 88: 306–314.

    PubMed  Google Scholar 

  18. Saiz A, Blanco Y, Berenguer J, Gómez-Choco M, Carreras E, Arbizu T et al. Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurologia 2008; 23: 405–407.

    CAS  PubMed  Google Scholar 

  19. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V et al. Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol 2000; 20: 24–30.

    Article  CAS  PubMed  Google Scholar 

  20. Grigg A, Tubridy NJ, Szer J, Mitchell P, Butzkueven H, Shuttleworth P et al. Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis. Intern Med J 2004; 34: 66–69.

    Article  CAS  PubMed  Google Scholar 

  21. Hamerschlak N, Rodrigues M, Moraes DA, Oliveira MC, Stracieri AB, Pieroni F et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant 2010; 45: 239–248.

    Article  CAS  PubMed  Google Scholar 

  22. Kozák T, Havrdová E, Pit′ha J, Gregora E, Pytlík R, Maaloufová J et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000; 25: 525–531.

    Article  PubMed  Google Scholar 

  23. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B . Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006; 20: 485–489.

    Article  PubMed  Google Scholar 

  24. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6: 563–575.

    Article  CAS  PubMed  Google Scholar 

  25. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005; 105: 2601–2607.

    Article  CAS  PubMed  Google Scholar 

  26. Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, Lisukov IA, Kozlov VA et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008; 36: 922–928.

    Article  CAS  PubMed  Google Scholar 

  27. Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006; 84: 276–281.

    Article  PubMed  Google Scholar 

  28. Xu J, Ji BX, Su L, Dong HQ, Sun XJ, Liu CY . Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl) 2006; 119: 1851–1855.

    Article  Google Scholar 

  29. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E et al. Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006; 12: 814–823.

    Article  CAS  PubMed  Google Scholar 

  30. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102: 2373–2378.

    Article  CAS  PubMed  Google Scholar 

  31. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102: 2364–2372.

    Article  CAS  PubMed  Google Scholar 

  32. CAMMS223 Trial Investigators Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801.

    Article  Google Scholar 

  33. Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65: 1044–1051.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144–1151.

    Article  CAS  PubMed  Google Scholar 

  35. Snowden JA, Biggs JC, Milliken ST, Fuller A, Staniforth D, Passuello F et al. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplant 1998; 22: 1035–1041.

    Article  CAS  PubMed  Google Scholar 

  36. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147–2150.

    Article  CAS  PubMed  Google Scholar 

  37. Statkute L, Verda L, Oyama Y, Traynor A, Villa M, Shook T et al. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 317–329.

    Article  CAS  PubMed  Google Scholar 

  38. Snir O, Lavie G, Achiron A, Bank I, Ben-Aharon T, Sredni B et al. G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis. J Neuroimmunol 2006; 172: 145–155.

    Article  CAS  PubMed  Google Scholar 

  39. Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001; 28: 1–12.

    Article  CAS  PubMed  Google Scholar 

  40. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T . Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439–3441.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zohren F, Toutzaris D, Klärner V, Hartung HP, Kieseier B, Haas R . The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893–3895.

    Article  CAS  PubMed  Google Scholar 

  42. Uy GL, Rettig MP, Cashen AF . Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther 2008; 8: 1797–1804.

    Article  CAS  PubMed  Google Scholar 

  43. Cogle CR, Yachnis AT, Laywell ED, Zander DS, Wingard JR, Steindler DA et al. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet 2004; 363: 1432–1437.

    Article  CAS  PubMed  Google Scholar 

  44. Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B . Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci USA 2003; 100: 1364–1369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lu JQ, Storek J, Metz L, Yong VW, Stevens AM, Nash RA et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol 2009; 66: 116–120.

    Article  PubMed  Google Scholar 

  46. Rice CM, Mallam EA, Whone AL, Walsh P, Brooks DJ, Kane N et al. Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 2010; 87: 679–685.

    Article  CAS  PubMed  Google Scholar 

  47. Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009; 32: 2041–2046.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Berisso GA, van Lint MT, Bacigalupo A, Marmont AM . Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves’ disease. Bone Marrow Transplant 1999; 23: 1091–1092.

    Article  CAS  PubMed  Google Scholar 

  49. Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Mech FG et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 46–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 2004; 127: 996–1008.

    Article  PubMed  Google Scholar 

  51. Atkins H, Freedman M . Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol 2009; 549: 231–246.

    Article  CAS  PubMed  Google Scholar 

  52. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J et al. Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) working party on autoimmune diseases. Haematologica 2010; 95: 284–292.

    Article  PubMed  Google Scholar 

  53. Stem cell therapy for patients with multiple sclerosis failing interferon A randomized study. Available from http://www.clinicaltrials.gov/ct21/show/record/NCT00273364.

  54. ASTI MS (Autologous Stem cell Transplantation International Multiple Sclerosis). Available from: http://www.astims.org.

  55. HALT-MS (High Dose Immunosuppression and Autologous Stem Cell Transplantation for Poor Prognosis Multiple Sclerosis). Available from: http://www.halt-ms.org and www.clinicaltrials.gov/ct21/show/record/NCT00288626.

  56. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9: 583–591.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK . Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant 2002; 29: 81–85.

    Article  CAS  PubMed  Google Scholar 

  58. Loh Y, Oyama Y, Statkute L, Yaung K, Gonda E, Barr W et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007; 109: 2643–2548.

    Article  CAS  PubMed  Google Scholar 

  59. Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 2005; 11: 862–870.

    Article  PubMed  Google Scholar 

  60. van Gelder M, van Bekkum DW . Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 1995; 16: 343–351.

    CAS  PubMed  Google Scholar 

  61. Van Wijmeersch B, Sprangers B, Rutgeerts O, Lenaerts C, Landuyt W, Waer M et al. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect. Biol Blood Marrow Transplant 2007; 13: 627–637.

    Article  CAS  PubMed  Google Scholar 

  62. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579–1586.

    Article  CAS  PubMed  Google Scholar 

  63. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57: 1192–1203.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755–1761.

    Article  CAS  PubMed  Google Scholar 

  65. Rafei M, Birman E, Forner K, Galipeau J . Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17: 1799–1803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009; 15: 644–646.

    Article  CAS  PubMed  Google Scholar 

  67. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4: 50–57.

    PubMed  Google Scholar 

  68. Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant 2010; 45: 1014–1021.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ottawa Hospital Blood and Marrow Transplant Programme, The Ottawa Hospital, Ottawa, Ontario, Canada

    H Atkins

Authors
  1. H Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Atkins.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atkins, H. Hematopoietic SCT for the treatment of multiple sclerosis. Bone Marrow Transplant 45, 1671–1681 (2010). https://doi.org/10.1038/bmt.2010.168

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.168

Keywords

This article is cited by

Search

Advanced search

Quick links